financetom
Business
financetom
/
Business
/
Why UP Fintech Holding (TIGR) Stock Is Falling
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why UP Fintech Holding (TIGR) Stock Is Falling
Oct 22, 2024 12:25 PM

UP Fintech Holding Ltd ( TIGR ) shares are trading lower by 8% to $6.84 Tuesday morning. The company announced a proposed follow-on public offering of 15 million American depository shares.

UP Fintech ( TIGR ) says the underwriters have the option to purchase an additional 2.25 million ADSs within 20 days of the prospectus supplement.

The proceeds from the offering will be used to strengthen the company’s capital base and support business development. Deutsche Bank, China International Capital Corporation and US Tiger Securities are acting as joint bookrunners for the offering.

Read Also: General Motors Q3 Earnings: Revenue And EPS Beat, Raises Annual Profit Outlook On Growing Consumer Demand

Should I Sell My TIGR Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of UP Fintech Holding ( TIGR ) have increased by 43.98% in the past year. An investor who bought shares of UP Fintech Holding ( TIGR ) at the beginning of the year would make a profit of $2.74 per share if they sold it today. The stock has risen 81.21% over the past month, meaning an investor who bought shares on Sep. 1 would see a capital gain of $3.22.

UP Fintech Holding ( TIGR ) shares have an all-time high of $12.39, representing 80.41% upside from current levels.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.

According to data from Benzinga Pro, TIGR has a 52-week high of $14.46 and a 52-week low of $3.10.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
A Trump presidency to pose mostly bearish risks for oil, Citi says
A Trump presidency to pose mostly bearish risks for oil, Citi says
Jul 25, 2024
(Reuters) - A Donald Trump presidency could be net bearish for oil prices due to a combination of factors including tariffs and oil-friendly policies, and pushing the Organization of the Petroleum Exporting Countries and allies (OPEC+) to release more oil into the market, Citi said in a research note on Thursday. Trump could roll back environmental policies, though broadly overturning...
GM's Cruise looks to start charging for robotaxi rides next year, Bloomberg News reports
GM's Cruise looks to start charging for robotaxi rides next year, Bloomberg News reports
Jul 25, 2024
(Reuters) -General Motors' ( GM ) self-driving technology unit, Cruise, aims to return to running fully autonomous rides later this year and charge fares by early 2025, Bloomberg News reported on Thursday, citing people familiar with the matter. The division had said earlier this week it would focus on developing a next-generation Chevrolet Bolt car instead of a planned Origin...
Constellium Prices Private Senior Note Offerings
Constellium Prices Private Senior Note Offerings
Jul 25, 2024
01:51 PM EDT, 07/25/2024 (MT Newswires) -- Constellium (CSTM) priced private offerings of senior unsecured notes of 300 million euros ($325.9 million) and $350 million, both due 2032. The euro notes will have a 5.375% annual interest rate with the dollar notes at 6.375%, both paid semiannually in arrears with possible adjustments, the company said Thursday in a statement. The...
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Jul 25, 2024
Thursday, Chemomab Therapeutics Ltd ( CMMB ). released topline results from the Phase 2 SPRING trial assessing its monoclonal antibody, CM-101, in patients with primary sclerosing cholangitis (PSC). Treatment with CM-101 achieved its primary endpoint of safety and tolerability. It demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across various disease-related secondary efficacy endpoints, including statistically significant improvement in liver stiffness. CM-101...
Copyright 2023-2026 - www.financetom.com All Rights Reserved